Natera, Germany’s Kupando Partner to Track ctDNA Dynamics in Phase 1 Skin Cancer Trial

The test will monitor circulating tumor DNA dynamics in Kupando Therapeutics' Phase 1 trial of KUP-101 in patients with advanced skin cancers.